D. Graham

Kelley E. Capocelli, M. Lovell, D. Graham, 2010, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia

D. Wechsler, M. Bhasin, Bhakti Dwivedi, 2021, Nature communications.

Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia

Christopher D. Scharer, M. Rupji, Bhakti Dwivedi, 2022, Nature communications.

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Kristen M. Jacobsen, S. Frye, H. Earp, 2018, JCI insight.

Disseminated nasopharyngeal natural killer cell lymphoblastic lymphoma in a child.

D. Graham, L. Stork, Xiayuan Liang, 2003, Medical and pediatric oncology.

Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children

A. Alsultan, N. Goldenberg, T. Hays, 2009, Pediatric blood & cancer.

BPTF Regulates Growth of Adult and Pediatric High-Grade Glioma through the MYC Pathway

Kristen L Jones, K. Ligon, N. Serkova, 2019, Oncogene.

Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.

S. Frye, D. Drewry, Yuewei Zhang, 2018, Journal of medicinal chemistry.

Varicella Zoster Virus Infections in the Pediatric Stem Cell Transplant Patient

R. Giller, D. Graham, 2000 .

MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.

D. DeRyckere, D. Graham, Diana M Fridlyand, 2020, Pharmacology & therapeutics.

The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

K. Davies, H. Earp, H. Earp, 2014, Nature Reviews Cancer.

Cloning and developmental expression analysis of the murine c-mer tyrosine kinase.

H. Snodgrass, W. Stanford, H. Earp, 1995, Oncogene.

Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr

H. Snodgrass, H. Earp, D. Graham, 2022 .

Rodent L1 evolution has been driven by a single dominant lineage that has repeatedly acquired new transcriptional regulatory sequences.

C. Hutchison, M. Edgell, N. Adey, 1994, Molecular biology and evolution.

Targeting the TAM Receptors in Leukemia

H. Earp, H. Earp, D. DeRyckere, 2016, Cancers.

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

H. Earp, D. Graham, H Shelton Earp, 2008, Advances in cancer research.

BAC to the future? comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities

S. Hunger, D. Graham, 2008, Pediatric blood & cancer.

Epigenetics and chemoresistance in childhood acute lymphoblastic leukemia

T. P. Newton, C. Cummings, D. Graham, 2014 .

Epigenetics and chemoresistance in childhood acute lymphoblastic

T. P. Newton, C. Cummings, D. Graham, 2014 .

Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia

Christopher D. Scharer, M. Rupji, Bhakti Dwivedi, 2022, Nature Communications.

Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer

W. Franklin, A. Baron, L. Heasley, 2012, Oncogene.

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

Melissa L. Kemp, W. Lam, H. Fu, 2022, bioRxiv.

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

S. Frye, J. Tyner, H. Earp, 2021, Cancers.

Molecular Genetic Analysis of a Small Bowel Primitive Neuroectodermal Tumor

M. Lovell, D. Graham, L. Stork, 2002, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

H. Earp, D. DeRyckere, D. Graham, 2021, Cancers.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

Katherine R. Singleton, A. Tan, L. Heasley, 2013, Oncogenesis.

LYMPHOID NEOPLASIA Mer receptor tyrosine kinase is a therapeutic target in pre – B-cell acute lymphoblastic leukemia

Kristen M. Jacobsen, A. Tan, H. Earp, 2013 .

Keypoints

Kristen M. Jacobsen, A. Tan, H. Earp, 2019, Encyclopedia of Biometrics.

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Kristen M. Jacobsen, D. DeRyckere, D. Graham, 2009, Blood.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, H. Martinson, 2013, Oncogene.

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia

D. DeRyckere, D. Graham, S. Christoph, 2013, Blood Cancer Journal.

Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase

L. Meltesen, A. Anwar, G. Johnson, 2006, Oncogene.

Abstract 240: MERTK inhibition induces an anti-leukemia dendritic cell - T cell axis while TYRO3 inhibition protects through a separate mechanism

S. Frye, Xiaodong Wang, H. Earp, 2022, Cancer Research.

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

D. Newton, S. Frye, W. Janzen, 2014, Journal of medicinal chemistry.

Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia.

D. DeRyckere, D. Graham, S. Christoph, 2013, Journal of visualized experiments : JoVE.

Ectopic Expression of the Proto-oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia

H. Snodgrass, M. Schell, J. Kurtzberg, 2006, Clinical Cancer Research.

Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies

D. DeRyckere, D. Graham, R. Summers, 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.

TYRO3 (TYRO3 protein tyrosine kinase)

Kristen M. Jacobsen, D. Graham, R. Linger, 2011 .

The Emerging Role of TYRO3 as a Therapeutic Target in Cancer

Xiaodong Wang, D. DeRyckere, D. Graham, 2018, Cancers.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

H. Earp, D. Graham, A. Keating, 2010, Expert opinion on therapeutic targets.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

H. Earp, S. Hunsucker, H. Martinson, 2013, Oncogene.

Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis.

D. Huhn, W. Siegert, H. Snodgrass, 1994, Blood.

Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A

N. Goldenberg, T. Hays, D. Graham, 2004, Pediatric blood & cancer.

Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria.

G. Brodsky, J. V. Van Hove, D. Graham, 2011, Molecular genetics and metabolism.

A Common Case of Cell Line Misidentification

Kristen M. Jacobsen, D. DeRyckere, D. Graham, 2014 .

GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis

J. Di Paola, B. Branchford, D. Graham, 2018, Front. Med..

The MERTK Signalling Pathway in Cancer

A. Hill, D. DeRyckere, D. Graham, 2015 .

GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis

J. Di Paola, B. Branchford, D. Graham, 2018, Front. Med..

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

S. Frye, S. Eckhardt, J. Tentler, 2018, Molecular Cancer Therapeutics.

Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations

N. Serkova, J. DeGregori, A. Hill, 2014, Clinical Cancer Research.

UNC5293, a potent, orally available and highly MERTK-selective inhibitor.

S. Frye, Xiaodong Wang, H. Earp, 2021, European journal of medicinal chemistry.

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme

S. Frye, M. Varella‐Garcia, J. Kowalski, 2016, PloS one.

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

K. Davies, H. Earp, C. Cummings, 2014, OncoTarget.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer

H. Earp, C. Cummings, D. DeRyckere, 2013 .

Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer

H. Earp, C. Cummings, D. DeRyckere, 2013 .

Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology

A. Pierce, D. Graham, S. Sather, 2012, Oncogene.

Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus

D. DeRyckere, D. Graham, J. Schlegel, 2012, PloS one.

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

S. Frye, W. Janzen, M. Machius, 2012, ACS medicinal chemistry letters.

Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Amy Lynnette Van Deusen, S. Frye, W. Janzen, 2012 .

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents

S. Frye, P. Harari, K. Davies, 2018, Molecular Cancer Therapeutics.

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

H. Fu, Yuhong Du, S. Moore, 2023, bioRxiv.

Data-driven construction of anti-tumor agents with controlled polypharmacology.

Laura E. Herring, S. Frye, M. Miley, 2019, Journal of the American Chemical Society.

Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment

S. Frye, H. Earp, Xiaodong Wang, 2023, Frontiers in Immunology.

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia

S. Frye, H. Earp, A. Hill, 2016 .

Moderate Aplastic Anemia in Children: Preliminary Outcomes for Treatment Versus Observation From a Single-Institutional Experience

N. Goldenberg, T. Hays, D. Graham, 2013, Journal of pediatric hematology/oncology.

CONSENSUS ON A CORE CURRICULUM IN AMERICAN TRAINING PROGRAMS IN PEDIATRIC HEMATOLOGY–ONCOLOGY: A Report from the ASPHO Training Committee

D. Wechsler, T. Abshire, D. Graham, 2007, Pediatric hematology and oncology.

Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition

S. Frye, T. P. Newton, H. Earp, 2014 .

Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening

Andrés J. García, E. Botchwey, S. Thomas, 2022, Advanced materials.

Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling

M. Bhasin, Bhakti Dwivedi, D. DeRyckere, 2020 .

The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

S. Frye, X. Wang, H. Earp, 2018, Journal of thrombosis and haemostasis : JTH.

MERTK (c-mer proto-oncogene tyrosine kinase)

D. Graham, A. Keating, R. Linger, 2011 .

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

S. Frye, W. Janzen, H. Earp, 2013, Molecular Cancer Therapeutics.

Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression

Shiyong Li, H. Broxmeyer, Sumin Kang, 2019, Nature Metabolism.

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.

S. Frye, M. Machius, M. Miley, 2016, ACS medicinal chemistry letters.

Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma

David B. Darr, N. Sharpless, S. Frye, 2014 .

Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia

S. Frye, W. Janzen, H. Earp, 2014 .

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

N. Popitsch, H. Kohrt, R. Sullivan, 2013, Clinical Cancer Research.

Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.

Melissa L. Kemp, W. Lam, H. Fu, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis

D. DeRyckere, D. Graham, S. Castellino, 2023, Scientific reports.

TAM family kinases as therapeutic targets at the interface of cancer and immunity

H. Earp, D. DeRyckere, D. Graham, 2023, Nature Reviews Clinical Oncology.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, J. M. Shields, 2013, The Journal of clinical investigation.

UNC 569 , a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo

S. Frye, W. Janzen, H. Earp, 2013 .

Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML

Xiaodong Wang, Yuhong Du, D. DeRyckere, 2023, Pharmaceutical Research.

Gray Zone Lymphomas in Pediatric Patients

R. Giller, D. Graham, B. Greffe, 2011, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations

N. Serkova, J. DeGregori, A. Hill, 2014, Clinical Cancer Research.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

Melissa A. Sandahl, Kristen M. Jacobsen, H. Earp, 2013, The Journal of clinical investigation.

Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity

A. Thorburn, A. Donson, N. Foreman, 2010, Molecular Cancer Therapeutics.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, M. Machius, M. Miley, 2013, Journal of medicinal chemistry.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

TITLE: Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

S. Frye, Xiaodong Wang, S. Eckhardt, 2018 .